179 related articles for article (PubMed ID: 34923121)
1. Evolving pancreatic cancer treatment: From diagnosis to healthcare management.
Milella M; Bassi C; Boggi U; Brunetti O; Cavaliere A; Crippa S; De Vita F; Falconi M; Frassineti GL; Giommoni E; Macchini M; Malleo G; Silvestris N; Tudisco A; Vasile E; Reni M
Crit Rev Oncol Hematol; 2022 Jan; 169():103571. PubMed ID: 34923121
[TBL] [Abstract][Full Text] [Related]
2. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: An update on diagnosis and management.
Loveday BPT; Lipton L; Thomson BN
Aust J Gen Pract; 2019 Dec; 48(12):826-831. PubMed ID: 31774983
[TBL] [Abstract][Full Text] [Related]
4. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
Winner M; Goff SL; Chabot JA
Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
[TBL] [Abstract][Full Text] [Related]
7. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
Tesfaye AA; Philip PA
Clin Adv Hematol Oncol; 2019 Jan; 17(1):54-63. PubMed ID: 30843899
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
10. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.
Schwarz L; Katz MH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):727-40. PubMed ID: 26226907
[TBL] [Abstract][Full Text] [Related]
12. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
15. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.
Benavides M; Abad A; Ales I; Carrato A; Díaz Rubio E; Gallego J; García-Foncillas J; Grávalos C; Laquente B; Pericay C; Rivera F; Tabernero J; Aranda E
Clin Transl Oncol; 2014 Oct; 16(10):865-78. PubMed ID: 24728654
[TBL] [Abstract][Full Text] [Related]
16. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
17. [Evolution in the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma].
Van Daele D; Puleo F; Dumont R; Polus M; Loly C; Martinive P; Meunier P; Collignon J; Hendlisz A; Maréchal R; Louis E; Van Laethem JL
Rev Med Suisse; 2015 Aug; 11(483):1543-8. PubMed ID: 26502580
[TBL] [Abstract][Full Text] [Related]
18. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
Loehrer AP; Kinnier CV; Ferrone CR
Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
[No Abstract] [Full Text] [Related]
20. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
Kang CM; Hwang HK; Choi SH; Lee WJ
Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
